Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGEN2017 (ASV) with QS-21 in Resected Solid Tumors
NCT03673020Phase 1Completed
- Sponsor
- Agenus Inc.
- Start
- May 2019
- Primary completion
- Feb 2021
- Modality
- Recombinant Proteins and Enzymes, Split/Subunit Vaccines, Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AutoSynVax in solid tumor, sponsored by Agenus Inc. Primary endpoint: Incidence of Treatment-Emergence Adverse Events at 1 year. Started May 2019; status: completed.
02
Drugs
AutoSynVax
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03673020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03673020.